Collectively, our results reveal that the oncogenic function of GPR110 is an important mechanism, resulting in metastasis and CSC in breast cancer, and suggest that GPR110 is a potential candidate for TNBC target therapy. The gene discussed is ADGRF1; the disease is breast cancer.